leisure time -WSS

leisure time

author：fashion 2025-09-28 04:58:57 - browse：1844

Person wearing a smart watch. -- first opinion coverage from STAT — Adobe

The Apple Watch has secured a new qualification from the Food and Drug Administration that could make the smartwatch an appealing tool for medical device companies hoping to illustrate the benefits of a common heart procedure.

Last week, the Apple Watch’s Atrial Fibrillation History feature became the first digital tool qualified under the Medical Device Development Tools (MDDT) program. Released in 2022, the feature estimates a user’s A-fib burden, or how much time they spend in atrial fibrillation, which is an irregular heart rhythm that can cause shortness of breath and fatigue, and is also linked to an increased risk of stroke.

The qualification means that FDA has determined in advance that sponsors can use the feature as a secondary endpoint in clinical trials without having to do additional work. Specifically, the Apple Watch is qualified for use as a secondary endpoint in clinical trials for cardiac ablation devices, which reduce the electrical signals that cause A-fib by scarring the heart with extreme heat or cold energy. Pulsed field ablation is the latest version of the technology, using a controlled electric field to scar tissue rather than the riskier thermal energy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Scientists successfully use ultrasound imaging to map brain activity

WSS

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Akili, maker of video game for ADHD, to be acquired for 34 million

iTeos Therapeutics debuts first data on TIGIT

Report: NIH

Chemotherapy drug shortage eases slightly but still widespread

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

explore

Cancer drug shortages should be causing more outrage

David Sabatini, ex

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

AI can decode, harness the power of the humane immune system

Cancer drug shortages should be causing more outrage

Latest bird flu infection made farmworker sicker than earlier cases

BioMarin wins approval for gene therapy to treat hemophilia A

AI can decode, harness the power of the humane immune system

Alkermes shareholders re

Antibiotic resistance nearly killed me, so I'm raising awareness of it

leisure time

Analysis of telehealth claims data suggest service duplication

Why age limits for politicians are a terrible idea

Childbirth

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Biohaven protein

Why age limits for politicians are a terrible idea

entertainment

explore

knowledge

entertainment